Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 Quick Ratio is 0.50 as of Dec. 2025, which is 7% below its 10-year median of 0.54. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Australian Clinical Labs ranks worse than 90.61% on this metric.
Australian Clinical Labs has a quick ratio of 0.50. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Australian Clinical Labs's Quick Ratio or its related term are showing as below:
ASX:ACL'
s Quick Ratio Range Over the Past 10 Years
Min: 0.45 Med: 0.54 Max: 0.74
Current: 0.5
During the past 6 years, Australian Clinical Labs's highest Quick Ratio was 0.74. The lowest was 0.45. And the median was 0.54.
ASX:ACL's Quick Ratio is ranked worse than 90.61% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.74
vs ASX:ACL: 0.50
Australian Clinical Labs (ASX:ACL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Australian Clinical Labs Quick Ratio Related Terms
Australian Clinical Labs Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Australian Clinical Labs's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Australian Clinical Labs's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a Quick Ratio of 0.50 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Australian Clinical Labs and its competitors. This is near median its historical median of 0.54. Over the past decade, Australian Clinical Labs' Quick Ratio has ranged from 0.45 to 0.74. According to the industry distribution chart, Australian Clinical Labs ranks #193 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 90.6%.
Is Australian Clinical Labs' Quick Ratio too high?
Australian Clinical Labs' current Quick Ratio of 0.50 is near median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 0.74. The Medical Diagnostics & Research industry median Quick Ratio is 1.74. Australian Clinical Labs' value of 0.50 is 71.3% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #193 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #193 out of 213 companies for Quick Ratio. This places Australian Clinical Labs in the lower half of its industry. The industry median Quick Ratio is 1.74. Australian Clinical Labs' value of 0.50 is 71.3% below this benchmark. Historically, Australian Clinical Labs' own Quick Ratio has ranged from 0.45 to 0.74 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 1.74, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.74, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current Quick Ratio of 0.50 is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current Quick Ratio is 0.50, which is near median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current Quick Ratio is 0.50, which is near median its 10-year median of 0.54 and 71.3% below the Medical Diagnostics & Research industry median of 1.74. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Quick Ratio is 0.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
Quick Ratio: 0.50 (near median its 10-year median of 0.54)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 71.3% below the Medical Diagnostics & Research median (#193 of 213)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
